BRD7 and neoplasm: Indeed, the tumor cells were significantly sensitized to the three CHK1 inhibitors, AZD7762, PF477736, and LY2603618, upon BRD7 silencing and CHK1 accumulation (Fig. 5B, lanes 5 versus 1), in a dose-dependent manner (Figs. 5A and S5A).